Company Valuation: GlaxoSmithKline Pharmaceuticals Limited

Data adjusted to current consolidation scope
Fiscal Period: March 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 281,714 224,319 329,173 487,432 386,822 487,296 -
Change - -20.37% 46.74% 48.08% -20.64% 25.97% -
Enterprise Value (EV) 256,351 207,663 329,173 487,432 386,822 487,296 487,296
Change - -18.99% 58.51% 48.08% -20.64% 25.97% 0%
P/E 16.6x 36.7x 55.8x 52.5x 37.3x 41.8x 36.3x
PBR 10.6x 12.9x 18.5x 25x 17.1x 18.4x 15.5x
PEG - -0.6x -16.49x 0.9x 3.2x 3.4x 2.4x
Capitalization / Revenue 8.59x 6.9x 9.53x 13x 10.1x 11.4x 10.3x
EV / Revenue 0x 0x 0x 0x 0x 11.4x 10.3x
EV / EBITDA 0x 0x 0x 0x 0x 32.8x 28.5x
EV / EBIT 0x 0x 0x 0x 0x 33.2x 28.5x
EV / FCF 0x 0x 0x 0x 0x 40.6x 37x
FCF Yield 2.75% 1.96% 1.67% 2.6% 2.19% 2.46% 2.7%
Dividend per Share 2 30 32 32 42 57 29.5 29.5
Rate of return 1.8% 2.42% 1.65% 1.46% 2.5% 1.03% 1.03%
EPS 2 100 36.05 34.83 54.76 61.15 68.78 79.18
Distribution rate 30% 88.8% 91.9% 76.7% 93.2% 42.9% 37.3%
Net sales 1 32,780 32,517 34,537 37,492 38,217 42,568 47,241
EBITDA 1 8,273 8,043 9,087 11,774 13,092 14,836 17,070
EBIT 1 7,592 7,385 8,390 11,106 12,428 14,698 17,112
Net income 1 16,947 6,107 5,900 9,276 10,360 11,654 13,418
Net Debt -25,363 -16,656 - - - - -
Reference price 2 1,662.95 1,324.15 1,943.10 2,877.30 2,283.40 2,876.50 2,876.50
Nbr of stocks (in thousands) 169,406 169,406 169,406 169,406 169,406 169,406 -
Announcement Date 5/16/22 5/17/23 5/17/24 5/13/25 5/13/26 - -
1INR in Million2INR
Estimates

P/E, Detailed evolution



P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
41.75x - - 1.03% 5.09B
33.27x12.06x24.51x0.59% 1,043B
29.94x6.66x18.64x2% 649B
33.54x7.85x16.21x2.59% 469B
19.72x4.82x11.95x2.75% 355B
20.01x5.21x12.94x3.07% 270B
21.55x4.46x12.7x1.98% 262B
26.04x6.76x12.04x2.46% 222B
-46.18x6.71x26.22x2.16% 189B
11.59x4.21x8.76x4.34% 175B
Average 19.12x 6.53x 16.00x 2.29% 363.81B
Weighted average by Cap. 23.96x 7.81x 18.02x 1.97%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA



Year-on-year evolution of the Yield

  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. Valuation GlaxoSmithKline Pharmaceuticals Limited
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!